Torrent Pharma Q1 FY27 Revenue Surges 55% YoY to ₹4,921 Crore; Net Profit ₹566 Crore
Torrent Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹4,921 crore, up 55% YoY. Net profit after tax was ₹566 crore. The India business revenue grew 19% to ₹2,157 crore. US revenue increased 36% to ₹418 crore. JB Business revenue was up 10% to ₹1,201 crore.
The substantial year-on-year growth in revenue and profit, coupled with market share gains in key segments and geographies, indicates a significant positive impact on the company's financial health and market position.
The company reported strong year-on-year growth in revenue and operating EBITDA, indicating positive business performance across segments and geographies. Key markets like India and the US showed significant growth.
Torrent Pharmaceuticals Limited announced its financial results for the first quarter of FY27, reporting a consolidated revenue of ₹4,921 crore, a significant increase of 55% year-on-year. The operating EBITDA stood at ₹1,664 crore, up 61% YoY, with an EBITDA margin of 33.8%. The net profit after tax for the quarter was ₹566 crore, a 3% increase from the previous year.
The company's base business revenues reached ₹3,720 crore, showing a 17% growth, with operating EBITDA at ₹1,240 crore, up 20% and margins at 33.3%. The India business demonstrated robust performance with revenues at ₹2,157 crore, a 19% increase, outperforming the IPM growth of 12%. Torrent Pharmaceuticals has achieved the number one rank in the IPM cardiac market and continues to show strong outperformance in this segment. The Gx Semaglutide product recorded a 36% market share in Q1 FY27.
Internationally, Brazil reported revenues of ₹277 crore, up 27% in constant currency. The US market saw revenues of ₹418 crore, a 36% increase, driven by new launches and one-time opportunities. Germany's revenues were ₹318 crore, up 3% in constant currency, though impacted by supply disruptions.
The JB Business segment recorded revenues of ₹1,201 crore, a 10% increase. Operating EBITDA for this segment grew by 34% to ₹424 crore, with margins at 35.3%. Exceptional items for the quarter amounted to ₹19 crore, primarily due to an inventory write-off consequent to a fire incident at an erstwhile JB Pharma warehouse.
Ameera Shah will be completing her term as an Independent Director on August 1, 2026. The Board meeting commenced at 02:00 pm and concluded at 04:40 pm on July 30, 2026.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.